Introduction: Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T 1/2 ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims: To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A. Methods: PTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 AE 10 IU kg À1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg À1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 AE 5 IU kg
Introduction
Haemophilia A, an X chromosome-linked recessive bleeding disorder, is characterized by a deficiency of coagulation factor VIII (FVIII). Patients with haemophilia A are at risk for acute bleeding which characteristically involves joints, but may also affect muscle and other soft tissues [1, 2] . Depending on the anatomic site, bleeding may be severe or even life threatening. Prophylaxis with FVIII is the optimal treatment for haemophilia A patients without inhibitors [3, 4] . When begun at a young age, it may prevent the development of haemophilic arthropathy, thereby decreasing the rate of disability and maintaining quality of life [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Prophylactic regimens with standard FVIII products require infusions every other day or three times weekly to effectively prevent or reduce spontaneous bleeds [6, [14] [15] [16] .
FVIII-rurioctocog alfa pegol (BAX 855 1 ) is a recombinant FVIII (rFVIII) modified with polyethylene glycol (PEG) that was developed to extend half-life (T 1/2 ) thereby reducing prophylactic infusion frequency while maintaining or improving haemostatic efficacy. BAX 855 is manufactured by covalently binding a branched 20 kDa PEG reagent to FVIII-octocog alfa (ADVATE) 2 , a full-length, unmodified rFVIII using proprietary technology from Nektar Therapeutics 3 [17] .
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Once haemostatic efficacy and safety of BAX 855 were established in subjects ≥12 years of age [18] , a study in paediatric previously treated patients (PTPs) with severe haemophilia A was conducted to evaluate immunogenicity, pharmacokinetics (PK), efficacy, safety and health-related quality of life (HrQoL) of BAX 855.
Materials and methods
The study was performed in accordance with the International Conference on Harmonisation Good Clinical Practice Guidelines. The study protocol and informed consent form received approval by the appropriate independent ethics committees. Written informed consent was obtained from the subjects' legally authorized representatives prior to performing any study-related procedures. The study was registered at www.clinicaltrials.gov as NCT02210091 and at clinicaltrialsregister.eu as 2014-000742-30.
Study design
This Phase 3, prospective, uncontrolled, multicenter, open label study evaluated immunogenicity, PK, efficacy, safety and HRQoL of BAX 855 in paediatric PTPs with severe haemophilia A. Two age cohorts (<6 and 6 to <12 years) of 30 subjects each were planned. All subjects were to receive twice-weekly prophylaxis (in 3-4 days intervals) with 50 AE 10 IU kg À1 of BAX 855 over a period of 6 months (≥50 exposure days [EDs] ). This treatment regimen was designed to ensure that most subjects maintained FVIII levels above 1%. Dose and frequency were selected taking into account the 1.4-to 1.5-fold extended T 1/2 of BAX 855 compared to ADVATE [18] and the subjects' age, as children present with higher FVIII clearance, resulting in a lower FVIII half-life and recovery [19, 20] . The dose could be increased up to 80 IU kg À1 according to predefined criteria described in the Data S1.
Prior to initiation of prophylaxis, 14 subjects per age cohort were to receive single infusions of 60 AE 5 IU kg À1 of ADVATE and BAX 855 to determine the PK profile of BAX 855 compared to ADVATE.
BAX 855 was used for bleeding treatment based on guidelines provided in the Data S1.
Sampling for immunogenicity, incremental recovery (IR) and clinical laboratory parameters was performed at baseline, Week 5 AE 1 or 10-15 EDs, Week 12 AE 2 and Month 6 AE 2 weeks (≥50 EDs).
Patient population
Key eligibility criteria included a diagnosis of severe haemophilia A (FVIII activity <1%), age <12 years, previous FVIII exposure ≥50 EDs for children <6 and ≥150 EDs for children 6 to <12 years of age, no history of and no detectable FVIII inhibitors at screening. A complete list of inclusion and exclusion criteria is provided in the Data S1.
Outcome measures
The primary outcome measure was the incidence of confirmed FVIII inhibitors (≥0.6 BU using the Nijmegen modification of the Bethesda assay determined at the central laboratory).
Other safety outcomes included binding antibodies to FVIII, PEG-FVIII, PEG and Chinese hamster ovary (CHO) proteins (as potential impurities from the manufacturing process) analysed using validated enzymelinked immunosorbent assays. Occurrence of (serious) adverse events ([S]AEs) related to BAX 855 and clinically significant changes in vital signs (pulse, respiration, supine blood pressure and temperature) and clinical laboratory parameters (haematology, clinical chemistry and lipids) were also assessed.
PK outcome measures, assessed by one-stage clotting and chromogenic substrate assays at a central laboratory, included mean residence time (MRT), T 1/2 , clearance (CL), area under the concentration vs. time curve (AUC) and IR after single doses of ADVATE and BAX 855. IR of BAX 855 over the course of the study was also determined.
Haemostatic efficacy of prophylactic treatment was assessed in terms of annualized bleeding rates (ABRs). Other efficacy outcome measures included haemostatic efficacy rating at resolution of bleeding (using a 4-point scale described in the Data S1), number of infusions administered for bleeding treatment and weight-adjusted consumption.
Exploratory outcome measures comprised HRQoL over time assessed by the Pediatric Quality of Life Inventory TM (PedsQL) 4 [21, 22] , visual analogue Pain Scale [23] and Physical Activity Question Set [24, 25] . A description of these instruments and analytical methods is provided in the Data S1.
Analytical methods
The sample size of 50 evaluable subjects was based on regulatory guidance [26] .
For all outcome measures, descriptive statistics were presented by age stratum. Frequency counts and percentages were calculated for occurrence of FVIII inhibitors and binding antibodies to FVIII, PEG-FVIII, PEG and CHO proteins. For the primary endpoint, the number and proportion (Clopper-Pearson exact 95% confidence interval [CI]) of subjects who developed FVIII inhibitors following exposure to BAX 855 and of all subjects who did not develop inhibitors and had ≥50 EDs to BAX 855 were analysed.
For analysis of PK data, a non-linear mixed-effects model approach (population PK) was implemented. Based on the two-compartmental PK model as a structure model, random subject effect was considered through interindividual variability. Model and age effect on PK parameters were also explored. Individual empirical Bayesian estimates of PK parameters were generated on the basis of the final population PK model. In addition, point and interval estimates for PK parameters were derived by the non-compartmental estimation approach for flexible sampling designs [27, 28] . This approach allowed for a reduced schedule of three postinfusion blood draws during a 96-h period, which were randomly selected from three choices for each blood draw. The sampling scheme is provided in the Data S1.
ABRs were calculated as number of bleeds per observation time in years for descriptive statistics. Point estimates and confidence intervals were derived in a generalized linear model framework assuming a negative binomial distribution for the number of bleeds with a logarithmic link function and presence or absence of target joints and age at screening (<6 years vs. 6 to <12 years) as covariates, and the duration of the observation period in years as an offset.
Results

Patients
Seventy-three subjects were enrolled, 66 at 39 study sites were dosed: 32 aged <6 years and 34 aged 6 to <12 years. Of 64 subjects completing the study, 62 (31 per age cohort) had ≥50 EDs to BAX 855.
Two subjects in the older cohort discontinued prematurely: one was withdrawn by the sponsor because one eligibility criterion was not met (≥150 documented EDs in medical history), the other was withdrawn by the investigator after three minor/moderate traumatic bleeds. Thirty-one subjects, 14 in the younger and 17 in the older cohort, participated in the PK substudy. Subject disposition is provided in Fig. 1 .
Of 66 treated subjects, 65 (98.5%) were male and 1 (1.5%) was female; 43 (65.2%) were White, 17 (25.8%) Asian and 4 (6.1%) were Black/African American. The mean and median age was 6.0 years. Demographic and baseline data are provided in Table 1 .
Efficacy
Subjects received a median (Q1; Q3) dose of 51.3 (47.4, 53. 6) IU kg À1 of BAX 855 per infusion at a median (Q1; Q3) frequency of 1.9 (1.8, 1.9) infusions per week. Median (Q1; Q3) doses and dosing frequencies were similar in subjects <6 years (51. 6 ; 1.9 [1.8, 1.9] infusions per week). Of 66 treated subjects, 60 (90.9%) did not require prophylactic dose adjustment. The reported reasons for dose increase in six subjects included FVIII trough levels <1% and increased risk of bleeding, medical criteria (without further specification), frequent bleeding episodes and investigator decision following bleeding. However, three subjects had no bleeding events before . Injury-related bleeds were the main contributors to the total ABR with a point estimate (95% CI) for the mean of 2.09 (1.49-2.93; median 1.8) which was almost twice as high as the point estimate for the mean spontaneous ABR which was 1.16 (0.74-1.83; median 0). The point estimate (95% CI) for the mean joint ABR was 1.10 (0.64-1.91; median 0). Subjects without target joints at screening (52/66) had a point estimate (95% CI) for the mean ABR of 2.92 (2.02-4.24; median 2.0). By comparison, in subjects with target joints at screening (14/66), defined as a single joint (ankles, knees, hips or elbows) with ≥3 spontaneous bleeding episodes in any consecutive 6-month period, the point estimate (95% CI) for the mean ABR was 3.54 (1.89-6.64; median 2.1; Table 2 ). During prophylaxis on study, 10/14 subjects had at least one target joint revert to a non-target joint. In 8 of these 10 subjects, 4 with one and 4 with two target joints, all target joints resolved. No new target joints developed in any subject.
Fifteen subjects who had received twice-weekly FVIII infusions of a mean of 30.5 IU kg À1 prior to enrolment experienced a decrease in their historical median ABR of 6.0 (mean 5.6) to 2.0 (mean 2.6) during twice-weekly BAX 855 prophylaxis with a mean of 50.2 IU kg À1 per infusion. Likewise, in 33 subjects on pre-study prophylaxis with three infusions per week of a mean of 33.5 IU kg À1 each, ABR decreased from a median of 3.0 (mean 3.9) to 0.0 (mean 2.3) while on twice-weekly BAX 855 prophylaxis with 50.6 IU kg À1 per infusion. For five subjects treated on demand prior to the study, twice-weekly prophylaxis resulted in a median reduction in the ABR from 53.0 (mean 62.0) to 2.1 (mean 5.9).
Over the 6-month prophylactic treatment period, 38% (25/66) of subjects did not experience any bleeding, with a proportion of 41% (13/32) in the younger and 35% (12/34) in the older cohort. Overall, 67% (44/66) of subjects had no spontaneous bleeds and 73% (48/66) had no joint bleeds. Seventy bleeding events, all of minor or moderate severity, were treated with BAX 855 at a median (Q1; Q3) dose of 46.9 (28.4, 52.3) IU kg À1 per infusion which is close to the initial prophylactic dose.
The majority of bleeding episodes (82.9%; 58/70) was treated with one infusion, 8.6% (6/70) with two infusions, and 8.6% (6/70) with three or more infusions. Response to treatment was rated excellent or good for 90% (63/70) of all treated bleeding events (Table 3) .
Pharmacokinetics
BAX 855 demonstrated an extended PK profile compared to ADVATE at the same (60 AE 5 IU kg À1 ) dose level (Fig. 2) . Increases in T 1/2 MRT and AUC compared to ADVATE were similar in the younger and older cohorts (Table 4) . Depending on the PK model and FVIII assay (one-stage clotting or chromogenic substrate) used, T 1/2 and MRT increased by 1.3-to 1.5-fold, AUC by 1.2-to 1.8-fold and CL decreased by 0.5-to 0.8-fold compared to ADVATE (Table 5) .
IR at the 60 AE 5 IU kg À1 dose level was the same for BAX 855 and ADVATE at a mean of 1.9 (IU dL
. IR of BAX 855 remained consistent over time.
Patient-reported Outcomes and Quality of Life
Subjects experienced clinically meaningful improvement in their HRQoL after 6 months of twice-weekly prophylaxis with BAX 855 with significant improvement in both the Psychosocial Summary (P = 0.0026) and Physical Health Summary (P < 0.0001) PedsQL TM domain scores. Improvement over baseline was %, percentage of subjects in each category relative to the number of subjects in the relevant analysis set; n, number of subjects in each category; N, total number of subjects in the relevant analysis set; SD, standard deviation; max, maximum; min, minimum. *A target joint is defined as a single joint (ankles, knees, hips or elbows) with ≥3 spontaneous bleeding episodes in any consecutive 6-month period.
observed in all domains in both age cohorts, although in the younger cohort, changes did not reach statistical significance. Subjects also reported a significant reduction in pain (P = 0.049). Overall, a significant increase in the amount of physical activity (P = 0.019) was demonstrated after 6 months of BAX 855 prophylaxis.
Immunogenicity
None of the 66 subjects developed FVIII inhibitors during the study. Forty-five subjects tested negative for binding antibodies at any time point. Sixteen subjects tested positive for binding antibodies to FVIII, PEG-FVIII or PEG prior to BAX 855 exposure, but turned negative while on BAX 855 treatment. Five subjects developed anti-PEG-FVIII IgG antibodies during BAX 855 treatment: in two subjects, antibodies were transient, in two subjects binding antibodies developed only at study completion, and in one subject, they were present at Weeks 5, 12 and at study completion with decreasing titre. In none of these subjects, an impact on IR or efficacy, or a temporal association between the presence of binding antibodies and AEs was observed. No subject developed antibodies to CHO proteins.
Adverse events
Overall, 4 467 796 IU of BAX 855 were infused during 3565 EDs. A total of 156 AEs in 43 (65.2%) subjects was reported during the study. Four AEs in three subjects were serious including febrile neutropenia, pancytopenia, acute gastritis and abdominal pain. None of these SAEs was fatal and none was assessed to be related to BAX 855. All SAEs had resolved by study completion. An isolated moderate, non-serious AE of urticaria was observed in a subject with an allergic predisposition in his medical history. This event did not recur during continued exposure to BAX 855 and was judged to be not related to study treatment. No subject discontinued BAX 855 due to an AE.
Discussion
BAX 855 is a pegylated full-length rFVIII product with extended half-life designed to reduce the frequency of prophylactic infusions while maintaining or improving haemostatic efficacy in patients with haemophilia A. In this Phase 3, prospective, uncontrolled, multicenter study in 66 paediatric PTPs <12 years of age with severe haemophilia A, the immunogenicity, ABR, annualized bleeding rate; CI, confidence interval; n, number of subjects in the relevant analysis set; Q1, first quartile; Q3, third quartile. Point estimate and 95% CIs were obtained from a generalized linear model assuming a negative binomial distribution with logarithmic link function. The model includes the presence or absence of target joints and age category (<6 vs. ≥6 to <12) as covariates and the duration of the observation period as an offset. *A target joint is defined as a single joint (ankles, knees, hips or elbows) with ≥3 spontaneous bleeding episodes in any consecutive 6-month period.
efficacy, safety and HRQoL of BAX 855 prophylaxis were evaluated. PK characteristics were assessed in a subgroup of 31 subjects. This study was designed in compliance with regulatory guidance on the evaluation of FVIII in children <12 years [26] . Based on this guidance and given that haemophilia is a rare disease, comparison with a control group receiving prophylaxis with a conventional FVIII product was not within the scope of the study. However, to obtain information on the potential benefits of a long-acting FVIII concentrate, a comparison with prestudy prophylaxis was performed, taking the limitations of this approach into account.
During twice-weekly prophylaxis with BAX 855, the total ABR in children <12 years was similar to the ABR observed in subjects ≥12 years with BAX 855 at the same dosing frequency [18] and also compared favourably with published data on every-other-day treatment with non-modified FVIII preparations in children [6, 19, 29] , adolescents and adults [14, 30, 31] . ABRs were also comparable to rates reported in children, adolescents and adults for twice-weekly prophylaxis with a licensed longer-acting rFVIII product [32, 33] .
The number of target joints, although low in this paediatric population, decreased during the study and more than half of the subjects with pre-existing target joints lost all of them by study completion.
Subjects on twice weekly as well as subjects on three times weekly FVIII prophylaxis prior to the study benefitted from twice-weekly BAX 855 treatment. Comparisons with historical data should be interpreted with caution, in particular as no information on the rationale for and on compliance with the prestudy dose regimen is available and the subjects on twice-weekly prestudy prophylaxis with conventional FVIII product may have been underdosed. However, the observed decrease in the ABR during the study compared to the prestudy ABR was reflected in improved HRQoL outcomes: PedsQL, pain and physical activity scores improved even though 92.4% of subjects had already been on prophylaxis prior to this study.
No major bleeding events occurred during the study. Efficacy of BAX 855 in bleeding treatment in terms of ratings of 'excellent' or 'good' and in terms of infusions administered per bleeding event was comparable with results reported for other FVIII preparations in children [19, 29, 32] , adolescents and adults [14, 18, 30, 31, 33] .
It was the aim to limit the frequency of PK blood sampling in paediatric patients to three postinfusion samples. Therefore, PK parameters were determined by a non-linear modelling population PK approach. In addition, a non-compartmental approach was extended to sparse sampling [27, 28] . Modelling allows for unstructured sampling schemes with the drawback of uncertainty about the correct model to use (e.g. one-or two-compartmental structural model) and of potential technical difficulties in model fitting. The non-compartmental approach, using a linear approximation of the curve between two observed time points, does not experience fitting problems. As the two approaches are based on different concepts, the corresponding results can differ. In this study, both approaches demonstrated an increase in T 1/2 and MRT and a decrease in CL with BAX 855 compared to ADVATE, indicating that both models are suitable for estimation of PK parameters in sparse sampling designs. Fold increases in FVIII T 1/2 and MRT with BAX 855 compared to its parent compound ADVATE in children confirmed results observed in adult and adolescent patients [18] . Children present with a higher clearance and thus lower half-life and recovery of FVIII than adults [18] [19] [20] . This was taken into account when selecting a dose of 50 AE 10 IU kg
À1
per infusion which was demonstrated to be effective for bleeding prophylaxis.
Safety outcomes indicated no effect of FVIII pegylation on product safety. No adverse drug reactions and no discontinuations due to AEs were reported. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or haemostatic efficacy.
Conclusion
In conclusion, twice-weekly administration of BAX 855 was demonstrated to be safe and efficacious for prophylaxis of bleeding in paediatric subjects <12 years with severe haemophilia A. 
